{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T02:52:11Z","timestamp":1656643931108},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,2,18]],"date-time":"2015-02-18T00:00:00Z","timestamp":1424217600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00705-015-2364-8","type":"journal-article","created":{"date-parts":[[2015,2,16]],"date-time":"2015-02-16T21:44:04Z","timestamp":1424123044000},"page":"1105-1112","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Baseline factors associated with treatment response in patients infected with hepatitis C virus 1b by stratification of IL28B polymorphisms"],"prefix":"10.1007","volume":"160","author":[{"given":"Qihua","family":"Ling","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingyan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhui","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niehong","family":"Min","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binyi","family":"Shang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,18]]},"reference":[{"key":"2364_CR1","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1084\/jem.20130012","volume":"210","author":"S Bibert","year":"2013","unstructured":"Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N et al (2013) IL28B expression depends on a novel TT\/-G polymorphism which improves HCV clearance prediction. J Exp Med 210:1109\u20131116","journal-title":"J Exp Med"},{"key":"2364_CR2","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/hep.23528","volume":"51","author":"S Bruno","year":"2010","unstructured":"Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A et al (2010) Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 51:2069\u20132076","journal-title":"Hepatology"},{"key":"2364_CR3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.virol.2013.06.025","volume":"444","author":"M Derbala","year":"2013","unstructured":"Derbala M, Rizk NM, Al-Kaabi S, John A, Sharma M, El-Dweik N et al (2013) The predictive value of IL-28B rs129860, rs11881222, and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Virology 444:292\u2013300","journal-title":"Virology"},{"key":"2364_CR4","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/hep.26203","volume":"57","author":"JE Everhart","year":"2013","unstructured":"Everhart JE, Wright EC (2013) Association of \u03b3-glutamyl transferase (GGT) activity with treatment and clinical outcomes in chronic hepatitis C (HCV). Hepatology 57:1725\u20131733","journal-title":"Hepatology"},{"key":"2364_CR5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2005.04.009","volume":"43","author":"P Ferenci","year":"2005","unstructured":"Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL Jr et al (2005) Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)\/ribavirin. J Hepatol 43:425\u2013433","journal-title":"J Hepatol"},{"key":"2364_CR6","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL et al (2002) Peginterferon alfa-2a plus rivavirin for chronic hepatitis C virus infection. N Engl J Med 347:975\u2013982","journal-title":"N Engl J Med"},{"key":"2364_CR7","first-page":"1943","volume":"19","author":"J Garcia-Samaniego","year":"2013","unstructured":"Garcia-Samaniego J, Romero M, Granados R, Aleman R, Juan MJ, Suarez D et al (2013) Factors associated with early virological response to peginterferon-alpha-2a\/ribavirin in chronic hepatitis C. Wold J Gastroenterol 19:1943\u20131952","journal-title":"Wold J Gastroenterol"},{"key":"2364_CR8","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Felly J, Thomapson AJ, Simon JS, Shianna KV, Urban TJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399\u2013401","journal-title":"Nature"},{"key":"2364_CR9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54:1433\u20131444","journal-title":"Hepatology"},{"key":"2364_CR10","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","volume":"49","author":"MG Ghany","year":"2009","unstructured":"Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 49:1335\u20131374","journal-title":"Hepatology"},{"key":"2364_CR11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/1743-422X-9-123","volume":"9","author":"X Guo","year":"2012","unstructured":"Guo X, Zhao Z, Xie J, Cai Q, Zhang X, Peng L et al (2012) Prediction of response to pegylated-interferon-\u03b1 and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype. Virol J 9:123","journal-title":"Virol J"},{"key":"2364_CR12","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","volume":"140","author":"SJ Hadziyannis","year":"2004","unstructured":"Hadziyannis SJ, Sette H Jr, Morgen TR, Balan V, Diago M, Marcellin P et al (2004) Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140:346\u2013355","journal-title":"Ann Intern Med"},{"key":"2364_CR13","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Hanafiah","year":"2013","unstructured":"Hanafiah K, Groeger J, Flaxman AD, Wiersman ST (2013) Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:1333\u20131342","journal-title":"Hepatology"},{"key":"2364_CR14","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/hep.21159","volume":"43","author":"DM Jensen","year":"2006","unstructured":"Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ et al (2006) Early identification of HCV genotype 1 patients responding to 24\u00a0weeks peginterferon alpha-2a (40 KD)\/ribavirin therapy. Hepatology 43:954\u2013960","journal-title":"Hepatology"},{"key":"2364_CR15","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2011.03.006","volume":"55","author":"CM Lange","year":"2011","unstructured":"Lange CM, Zeuzem S (2011) IL28B single nucleotide polymorphisms in the treatment of hepatitis C. Hepatology 55:692\u2013701","journal-title":"Hepatology"},{"key":"2364_CR16","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jcv.2013.06.014","volume":"58","author":"I Lazarevic","year":"2013","unstructured":"Lazarevic I, Djordjevic J, Cupic M, Karalic D, Delic D, Svirtlih N et al (2013) The influence of single and combined IL28B polymorphisms on response to treatment of chronic hepatitis C. J Clin Virol 58:254\u2013257","journal-title":"J Clin Virol"},{"key":"2364_CR17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","volume":"358","author":"MP Manns","year":"2001","unstructured":"Manns MP, McHutchison JG, Gorden SC, Rustigi VK, Shiffman M, Reindollar R et al (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358:958\u2013965","journal-title":"Lancet"},{"key":"2364_CR18","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.23744","volume":"52","author":"TR Morgen","year":"2010","unstructured":"Morgen TR, Ghany MG, Kim HY, Snow KK, Shiffmann ML, De Santo JL et al (2010) Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52:833\u2013844","journal-title":"Hepatology"},{"key":"2364_CR19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","volume":"45","author":"L Prokunina-Olsson","year":"2013","unstructured":"Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dichensheets H et al (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45:164\u2013171","journal-title":"Nat Genet"},{"key":"2364_CR20","doi-asserted-by":"crossref","first-page":"e72600","DOI":"10.1371\/journal.pone.0072600","volume":"8","author":"V Saludes","year":"2013","unstructured":"Saludes V, Bascunana E, Jordana-Lluch E, Casanovas S, Ardevol M, Soler E et al (2013) Relevance of baseline viral genetic heterogeneity and host factors for treatment outcome prediction in hepatitis C virus 1b infected patients. PLoS One 8:e72600","journal-title":"PLoS One"},{"key":"2364_CR21","doi-asserted-by":"crossref","first-page":"e14132","DOI":"10.1371\/journal.pone.0014132","volume":"5","author":"V Saludes","year":"2010","unstructured":"Saludes V, Bracho MA, Valero O, Ardevol M, Planas R, Gonzalez-Candelas F et al (2010) Baseline prediction of combination therapy outcome in hepatitis C virus 1b infected patients by discriminant analysis using viral and host factors. PloS One 5:e14132","journal-title":"PloS One"},{"key":"2364_CR22","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cgh.2009.11.018","volume":"8","author":"AG Singal","year":"2010","unstructured":"Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS (2010) A sustained viral response is associated with reduced liver related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 8:280\u2013288","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2364_CR23","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","volume":"41","author":"Y Tanaka","year":"2009","unstructured":"Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al (2009) Genome wide association of IL28B with response to pegylated interferon alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41:1105\u20131109","journal-title":"Nat Genet"},{"key":"2364_CR24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1001\/jama.284.4.450","volume":"284","author":"DL Thomas","year":"2000","unstructured":"Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N et al (2000) The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284:450\u2013456","journal-title":"JAMA"},{"key":"2364_CR25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/jmv.23428","volume":"85","author":"H Toyada","year":"2013","unstructured":"Toyada H, Kumada T, Shimada N, Takaguchi K, Ide T, Sata M et al (2013) Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study. J Med Virol 85:65\u201370","journal-title":"J Med Virol"},{"issue":"14 Suppl","key":"2364_CR26","first-page":"S340","volume":"18","author":"TT Tran","year":"2012","unstructured":"Tran TT (2012) A review of standard and newer treatment strategies in hepatitis C. Am J Manag Care 18(14 Suppl):S340\u2013S349","journal-title":"Am J Manag Care"},{"key":"2364_CR27","doi-asserted-by":"crossref","first-page":"677","DOI":"10.7326\/0003-4819-147-10-200711200-00003","volume":"147","author":"BJ Veldt","year":"2007","unstructured":"Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S et al (2007) Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147:677\u2013684","journal-title":"Ann Intern Med"},{"key":"2364_CR28","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1007\/s00535-011-0458-y","volume":"46","author":"V Weich","year":"2011","unstructured":"Weich V, Herrmann E, Chung TL, Sarrazin C, Hinrichsen H, Buggisch P et al (2011) The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alphar based therapy in HCV type-1 infection. J Gastroenterol 46:1427\u20131436","journal-title":"J Gastroenterol"},{"key":"2364_CR29","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1111\/j.1440-1746.2007.04904.x","volume":"22","author":"JW Yu","year":"2007","unstructured":"Yu JW, Wang GQ, Sun LJ, Li XG, Li SC (2007) Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22:832\u2013836","journal-title":"J Gastroenterol Hepatol"},{"key":"2364_CR30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jhep.2010.11.019","volume":"55","author":"L Zhang","year":"2011","unstructured":"Zhang L, Jilg N, Shao RX, Lin W, Fusco DN, Zhao H et al (2011) IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 55:289\u2013298","journal-title":"J Hepatol"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-015-2364-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-015-2364-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-015-2364-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T00:58:52Z","timestamp":1559091532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-015-2364-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,18]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2364"],"URL":"https:\/\/doi.org\/10.1007\/s00705-015-2364-8","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,18]]}}}